Advertisement

Clinical and Translational Oncology

, Volume 14, Issue 6, pp 399–400 | Cite as

Evolution of tumour biology upon progression. Do we know our enemy?

  • Ana LluchEmail author
  • Ana Bosch
Editorial
  • 55 Downloads

References

  1. 1.
    Niikura N, Liu J, Hayashi N et al (2012) Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30:593–599PubMedCrossRefGoogle Scholar
  2. 2.
    Amir E, Miller N, Geddie W et al (2012) Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30:587–592PubMedCrossRefGoogle Scholar
  3. 3.
    Lower EE, Glass EL, Bradley DA et al (2005) Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treatment 90:65–70CrossRefGoogle Scholar
  4. 4.
    Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triplereceptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953–1958PubMedCrossRefGoogle Scholar
  5. 5.
    Castaneda CA, Andrés E, Barcena C et al (2012) Behavior of breast cancer molecular subtypes through tumour progression. Clin Transl Oncol 14:481–485PubMedGoogle Scholar
  6. 6.
    Ding L, Ellis MJ, Li S et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999–1005PubMedCrossRefGoogle Scholar
  7. 7.
    Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359:2814–2823PubMedCrossRefGoogle Scholar
  8. 8.
    Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892PubMedCrossRefGoogle Scholar
  9. 9.
    Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K et al (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10:1093–1101PubMedCrossRefGoogle Scholar
  10. 10.
    Slamon DJ, Leyland-Jones B, Shaks S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792PubMedCrossRefGoogle Scholar
  11. 11.
    Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 363:1693–1703PubMedCrossRefGoogle Scholar
  12. 12.
    Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2012

Authors and Affiliations

  1. 1.Servicio de Hematología y Oncología MédicaInstitute of Health Research INCLIVAValenciaSpain

Personalised recommendations